1. Home
  2. Media
  3. News
  4. Bioiberica to launch Aquasorb™, a range of products for dermatology

Bioiberica to launch Aquasorb™, a range of products for dermatology

18 Nov 2015
Science
  • Its formulation has been proved to reduce skin inflammation, irritation, and itchiness, as well as to improve the skin’s moisture content
  • Its formulation includes an innovative ingredient in dermatology, chondroitin sulfate, combined with sphingolipids, Omega-3 and hyaluronic acids, and Vitamins B2, B3 and B7
  • This range of products will be a useful complement for pharmacologic treatments, helping to control and reduce the frequency of clinical episodes
  • The research and development of this new product range has been carried out by Bioiberica

Bioibérica announced the launch of Aquasorb™, a range of products for atopic dermatitis and psoriasis. Its formulation includes an innovative ingredient in dermatology, chondroitin sulfate which, combined with sphingolipids, Omega-3 acids, hyaluronic acid and Vitamins B2, B3 and B7, has been scientifically proved to reduce skin inflammation, irritation and itchiness, while improving the skin’s moisture level.

 “Both atopic dermatitis and psoriasis are two skin conditions sharing a common trait-they are inflammatory condition that cause reddening and itchiness in the skin. The components of Aquasorb improve both conditions, thanks to its anti-inflammatory and anti-reddening effects”, explained Dr. Montserrat Pérez, Dermatologist at the Dr. Moragas Clinic in Barcelona.  

Aquasorb is sold in two formats: topical and oral. Each format contains different ingredients that result in higher efficacy. In an observational study with 32 patients suffering from atopic dermatitis, psoriasis or xeroderma, the product reached a global improvement of 78%. Furthermore, 80% of patients improved their erythema, desquamation, itching, hyperkeratosis and cracked or chapped skin.

 “Aquasorb’s oral and topical applications are scientifically studied formulations that have proved their positive effects at a clinical level. Chondroitin sulfate has been proved to reduce skin inflammation, while Omega-3 fatty acids reduce the severity of atopic dermatitis. Sphingolipids promote the synthesis of ceramides and the hyaluronic acid hydrates and provides elasticity to the skin”, added Daniel Martínez, R&D Director of Human Health at Bioiberica.

The Aquasorb products complement the pharmacologic treatment, for they help control and reduce the frequency of clinical episodes. It is recommended to apply the topical form of Aquasorb once or twice a day over the entire body’s surface or over the specific area to be treated This should be combined with three daily pills of Aquasorb Oral, taken together, over a three month period. After this first treatment, the patient may take a 2-3 month break then repeat the treatment following the same pattern. Oral treatment is especially preferred to prepare our skin for weather changes, for instance for the winter or before the spring-summer season. It can also be taken on a permanent basis to have an optimum skin hydration during the entire year. 

This upcoming 27th November we commemorate Atopic Dermatitis Day, a day dedicated to those suffering from this chronic inflammatory disease of the skin, which affects 20 percent of children and 7 percent of adults in our country.

The research and development of this new range of products has been carried out by Bioibérica, a Spanish biotech company specializing in the identification and production of high therapeutic value bio molecules out of tissues of animal origin.